Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $8 from $9 and keeps an Outperform rating on the shares following Q2 results. The firm notes Phase 1 trial of ACR-2316 is on track for the second half of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV: